Haemato-oncology clinical trials

Clinical trials are an important part of improving treatment for patients.

Acute leukaemias

Acute myeloid leukaemia (AML) trials

  • Trial of dual aurora kinase, FLT3 inhibitor for adults with AML relapsed or refractory to conventional therapy
  • Trial of MDM2 antagonist in combination with intensive chemotherapy for relapsed/refractory AML in fit adults
  • AML19 for untreated patients aged 18-60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
  • AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy

Acute lymphoblastic leukaemia (ALL) trials

  • MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults
  • Daratumumab plus chemotherapy for first relapsed/refractory T acute lymphoblastic leukaemia in young adults (<30 years)